MDA-231-BoM-1833 is a breast adenocarcinoma cell line established from bone metastasis of nude mice inculated with the parent cell line. It is a triple negative breast cancer (TNBC) cell line.
This cell line is part of a panel of human breast cancer cell lines selected to metastasize to specific organs.
This cell line was established from a 51-year-old female of Caucasian ethnicity and was derived from a metastatic site of pleural effusion.
Joan Massagué, PhD, Chief Scientific Officer, Director, Sloan Kettering Institute, and Laboratory Head, Cancer Biology & Genetics Program, MSK
This cell line is jointly owned with MD Anderson and is available for licensing through an interinstitutional agreement.
- Cox T et al. (2015) Dataset for the proteomic inventory and quantitative analysis of the breast cancer hypoxic secretome associated with osteotropism. Data in brief, 5, 621-625. (PubMed ID: 26649326)
- Kang y et al. (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer cell, 3(6), 537-549. (PubMed ID: 12842083)
- Minn A et al. (2005) Genes that mediate breast cancer metastasis to lung. Nature 436(7050) 518-524. (PubMed ID: 16049480)
- Selicharova I et al. (2008) 2-DE analysis of breast cancer cell lines 1833 and 4175 with distinct metastatic organ-specific potentials: comparison with parental cell line MDA-MB-231. Oncology reports, 19(5), 1237-1244. (PubMed ID: 18424382)
- RRID: CVCL_DP48